Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chapman, M.J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chapman, M.J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Elsevier Ltd

Are the effects of statins on HDL-cholesterol clinically relevant?

M.J. Chapman*

National Institute for Health and Medical Research (INSERM), Unit 551, Hôpital de la Pitié, Paris Cedex 13, France

* Correspondence: National Institute for Health and Medical Research, Hôpital de la Pitié, 83, boulevard de l'hôpital, 75651 Paris Cedex 13, France. Tel./fax: +33-1-45-82-81-98
chapman{at}chups.jussieu.fr

Abstract

It has been established that the level of plasma high-density lipoprotein (HDL)-cholesterol is inversely proportional to the risk of coronary heart disease (CHD). HDL particles are highly heterogeneous, particularly in terms of their biological activities, many of which are atheroprotective. For example, in addition to carrying out reverse cholesterol transport, HDL protects the vascular endothelium by inhibiting monocyte adhesion and the oxidative modification of low-density lipoprotein (LDL), eliminates some of the atherogenic products of LDL oxidation, and possesses antithrombotic activity, due to the inhibition of platelet activation and aggregation. Statin therapy has been shown to increase the level of plasma HDL-cholesterol. However, the clinical benefit of statin-induced elevation of HDL-cholesterol is unclear from trial data, perhaps as a result of the concomitant overwhelming risk benefit of statin-induced reduction of LDL-cholesterol.

Key Words: Atheroprotection • High-density lipoprotein • Low-density lipoprotein • Statin therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.